Myriad Genetics (MYGN)
(Real Time Quote from BATS)
$18.16 USD
-0.47 (-2.52%)
Updated Apr 25, 2024 12:00 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MYGN 18.16 -0.47(-2.52%)
Will MYGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MYGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MYGN
Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know
MYGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Myriad Genetics (MYGN) Announces Favorable Research Results
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
Other News for MYGN
Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor
New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen
Myriad Genetics announces new study published in Prenatal Diagnosis
MYGN Makes Notable Cross Below Critical Moving Average
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing